Anna Steeger
Chief Executive Officer bij PentixaPharm GmbH
Profiel
Anna Steeger is currently the Managing Director at Polyventures GmbH and the Co-Managing Director at PentixaPharm GmbH.
She is also the Managing Partner at 1717 Life Sciences Ventures GmbH since 2017.
Previously, she worked as an Independent Director at Eckert & Ziegler BEBIG SA.
Actieve functies van Anna Steeger
| Bedrijven | Functie | Begin |
|---|---|---|
| 1717 Life Sciences Ventures GmbH | Private Equity Investor | 01-01-2017 |
| Polyventures GmbH | Chief Executive Officer | - |
PentixaPharm GmbH
 PentixaPharm GmbH Miscellaneous Commercial ServicesCommercial Services Pentixapharm GmbH engages in the development, production, marketing, and distribution of medicines and radiopharmaceutical products, which act on the CXCR4 receptor. The company was founded on May 14, 2019 and is headquartered in Wuerzburg, Germany. | Chief Executive Officer | - |
Eerdere bekende functies van Anna Steeger
| Bedrijven | Functie | Einde |
|---|---|---|
| ECKERT & ZIEGLER BEBIG | Director/Board Member | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Eckert & Ziegler BEBIG SA
 Eckert & Ziegler BEBIG SA Pharmaceuticals: MajorHealth Technology Eckert & Ziegler BEBIG SA engages in the provision of medical devices. Its products include prostate seed brachytherapy, brain seed brachytherapy, high dose rate brachytherapy, ophthalmic brachytherapy and radiotherapy accessories. The company was founded on February 15, 1996, is headquartered in Seneffe, Belgium. | Health Technology |
| 1717 Life Sciences Ventures GmbH | Finance |
| Polyventures GmbH | |
PentixaPharm GmbH
PentixaPharm GmbH Miscellaneous Commercial ServicesCommercial Services Pentixapharm GmbH engages in the development, production, marketing, and distribution of medicines and radiopharmaceutical products, which act on the CXCR4 receptor. The company was founded on May 14, 2019 and is headquartered in Wuerzburg, Germany. | Commercial Services |
